CALCIPOTRIENE
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
| Metabolism | Calcipotriene undergoes extensive hepatic metabolism via cytochrome P450 enzymes (mainly CYP3A4, CYP2D6, and CYP1A2) to inactive metabolites, which are excreted in feces and urine. |
| Excretion | Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine. |
| Half-life | The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation. |
| Protein binding | Calcipotriene is approximately 94% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Due to extensive tissue binding and lipophilicity, the apparent volume of distribution (Vd) is estimated to be >5 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Systemic bioavailability after topical application is less than 1% when applied to normal skin (0.5–1.0%) and up to 5–6% when applied to psoriatic plaques due to increased permeability. |
| Onset of Action | Clinical improvement (reduction in scaling and plaque thickness) is typically observed within 2 weeks of twice-daily topical application; maximal effect may require 4–8 weeks of continuous therapy. |
| Duration of Action | The duration of action after topical application is variable, with effects persisting for several days to weeks after discontinuation. Continuous application is required to maintain remission; rebound may occur if treatment is stopped abruptly. |
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
| Dosage form | OINTMENT |
| Renal impairment | No adjustment required due to minimal systemic absorption. |
| Liver impairment | No adjustment required due to minimal systemic absorption. |
| Pediatric use | Children ≥2 years: apply 0.005% cream or ointment once daily, not exceeding 50 g per week. Safety and efficacy in children <2 years not established. |
| Geriatric use | No specific geriatric adjustment; use caution due to increased risk of skin irritation and potential for reduced renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Topical use only excessive use can lead to hypercalcemia.
| Breastfeeding | Excretion into breast milk unknown. Topical calcipotriene has low systemic absorption; however, avoid application to breast area to prevent infant ingestion. M/P ratio not available. Use with caution in nursing mothers only if clearly needed. |
| Teratogenic Risk | Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be ruled out. First trimester: insufficient data; second and third trimesters: avoid unless clearly needed. Topical application at recommended doses is unlikely to cause harm, but caution advised. |
■ FDA Black Box Warning
None.
| Common Effects | Skin irritation |
| Serious Effects |
["Hypercalcemia or evidence of vitamin D toxicity","Hypersensitivity to calcipotriene or any component of the formulation","Use on face, eyes, or mucous membranes"]
| Precautions | ["Hypercalcemia: Avoid exceeding recommended dose; monitor serum calcium, urine calcium, and serum phosphate in patients with renal impairment or when used with other vitamin D products.","Local skin reactions: Irritation, itching, erythema, burning; discontinue if severe.","Photosensitivity: Avoid excessive exposure to sunlight or artificial UV light.","Use on face, groin, or axillae may increase irritation.","Not recommended in patients with known disorders of calcium metabolism."] |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring | Maternal: no specific monitoring beyond standard prenatal care. Fetal: no routine monitoring indicated for topical use. If large areas are treated, consider checking maternal serum calcium levels due to potential hypercalcemia risk. |
| Fertility Effects | No known effects on fertility at typical topical doses. High-dose animal studies showed no impairment; human data lacking. |
| No specific food interactions. Maintain adequate calcium and vitamin D intake as per normal dietary recommendations. Avoid high-dose calcium or vitamin D supplements unless prescribed, as additive hypercalcemic risk. |
| Clinical Pearls | Calcipotriene is a synthetic vitamin D3 analog used primarily for plaque psoriasis. It works by inhibiting keratinocyte proliferation and promoting differentiation. Avoid use on the face, intertriginous areas, and anogenital region due to irritation risk. Maximum weekly dose should not exceed 100 g to avoid hypercalcemia. Use with caution in patients with renal impairment or known hypercalcemia. Combination with topical corticosteroids can enhance efficacy and reduce irritation. |
| Patient Advice | Apply a thin layer to affected areas only, avoiding healthy skin. · Wash hands after application unless treating hands. · Do not use on the face, groin, or skin folds unless specifically directed. · Do not exceed 100 grams per week to avoid side effects. · Avoid excessive sun exposure or tanning beds during treatment. · Inform your doctor if you experience signs of high calcium: nausea, vomiting, constipation, muscle weakness. · Use exactly as prescribed; do not use occlusive dressings unless instructed. · May cause local skin irritation; report severe reactions to your doctor. |